Too Old to Operate2d
Risks of AEs With Mirtazapine in Major Depressive Disorder
The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a ...
Using machine learning to predict how people diagnosed with major depressive disorder respond to treatment
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
WebMD3d
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
EurekAlert!3d
A new global study aims to map the brain signatures of bipolar disorder to transform understanding of the disease
A new study, led by USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), will explore structural ...
Medscape8d
Largest Study to Date Identifies Hundreds of Genes for Major Depression
The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...
WebMD9d
Living With Major Depressive Disorder
I’ve been living with depression for almost 12 years. I’m 31 now and I found out I had major depressive disorder when I was 19. I had a miserable freshman year of college, but I didn't really ...
psychiatryadvisor.com2d
Preventive Interventions Effective for Subthreshold Depressive Symptoms
(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...
Verywell Health on MSN2d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Neurocrine Amends Agreement With Takeda for Major Depressive Disorder Treatment
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
Interesting Engineering on MSN7d
US approves first nasal spray for major depressive disorder, PTSD conditions
Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...